Therapeutic strategies in epithelial ovarian cancer

Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.

• Publication year

  2012

• Venue

  Journal of experimental & clinical cancer research : CR

• Publication date

  2012-02-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1756-9966-31-14PMID 22330607PMCID 3309949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• THE CELL OF ORIGIN OF OVARIAN EPITHELIAL TUMORS

  2014cited by this paper
• Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

  2013cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Chemotherapy in epithelial ovarian cancer.

  2011cited by this paper
• Incorporation of bevacizumab in the primary treatment of ovarian cancer.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• The role of surgery in the management of epithelial ovarian cancer.

  2011cited by this paper
• A phase 3 trial of bevacizumab in ovarian cancer.

  2011cited by this paper
• OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

  2011cited by this paper
• Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

  2010cited by this paper
• Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.

  2010cited by this paper
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  2010cited by this paper
• The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010cited by this paper
• Overcoming platinum resistance in ovarian carcinoma

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

  2010cited by this paper
• Treatment of recurrent epithelial ovarian cancer

  2009cited by this paper
• Ovarian cancer.

  2009cited by this paper
• MedScape

  2009cited by this paper
• Ovarian cancer

  2009cited by this paper
• Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary: A JGOG Study

  2009cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

  2008cited by this paper
• The cell of origin of ovarian epithelial tumours.

  2008cited by this paper
• Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

  2008cited by this paper
• VEGF-targeted therapy: mechanisms of anti-tumour activity

  2008cited by this paper
• Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Correlation of Epidermal Growth Factor Receptor Expression with Tumor Microdensity Vessels and with Vascular Endothelial Growth Factor Expression in Ovarian Carcinoma

  2005cited by this paper
• Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

  2005cited by this paper
• Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

  2004cited by this paper
• Chemotherapy in advanced ovarian cancer

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

  2003cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003cited by this paper
• International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma.

  2003cited by this paper
• Chemotherapy in epithelial ovarian cancer.

  2002cited by this paper
• Clinical characteristics of clear cell carcinoma of the ovary

  2000cited by this paper
• Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.

  2000cited by this paper
• Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study.

  2000cited by this paper
• Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.

  1999cited by this paper
• Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

  1999cited by this paper
• Chemotherapy of advanced ovarian cancer.

  1998cited by this paper
• Chemotherapy of advanced ovarian cancer.

  1998cited by this paper
• Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview.

  1997cited by this paper
• Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

  1993cited by this paper
• Molecular genetics for the clinician

  1993influential reference
• Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.

  1991cited by this paper
• © 2001 Cancer Research Campaign

  year unknowncited by this paper

• Design and synthesis of novel triazole-metronidazole boswellic acid hybrids for ovarian cancer targeting.

  2026cites this paper
• Clove Aqueous Extract Triggers a Multi-Organellar Stress Crisis through Lysosomal Destabilisation and Mitochondrial Hyperpolarisation to Suppress Patient-Derived Ovarian Cancer Cells

  2026cites this paper
• CT deep learning radiomics and genomics for predicting staging of epithelial ovarian cancer.

  2026cites this paper
• Paclitaxel resistance-associated metabolic events in ovarian cancer cells

  2025cites this paper
• Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients

  2025cites this paper
• MEOX2 mediates cisplatin resistance in ovarian cancer via E2F target and DNA repair pathways

  2025cites this paper
• Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation/immunity and patient outcome

  2025cites this paper
• Novel gene rearrangement leads to altered expression of Hornerin in sensitive and chemoresistant ovarian cancer

  2025cites this paper
• Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response

  2025cites this paper
• PABPC3 drives ovarian cancer metastasis and drug sensitivity by downregulating CLDN1 expression

  2025cites this paper
• Molecular impact of NOTCH signaling dysregulation on ovarian cancer progression, chemoresistance, and taxane response

  2025cites this paper
• Body mass index and chemotherapy completion among patients with newly diagnosed ovarian cancer

  2025cites this paper
• Antibody-Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application.

  2025cites this paper
• Integrated multi-omics analysis reveals the immunotherapeutic significance of tumor cells with high FN1 expression in ovarian cancer

  2025cites this paper
• Shared chemoresistance genes in ESCC and cervical Cancer: Insights from pharmacogenomics and Mendelian randomization.

  2025cites this paper
• Utility of CA125 KELIM in predicting benefit from hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer: pooled analysis of KGOG3042 and KOV-HIPEC-01.

  2025cites this paper
• MiR-204-5p mediates PERK inhibition to suppress growth and induce apoptosis in ovarian cancer through the eIF2α/ATF-4/CHOP pathway

  2025cites this paper
• TRIM47 inhibits cisplatin chemosensitivity and endoplasmic reticulum stress-induced apoptosis of ovarian cancer cells.

  2024cites this paper
• Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy

  2024cites this paper
• Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes

  2024cites this paper
• Pre-operative plasma VEGF-C levels portend recurrence in epithelial ovarian cancer patients and is a bankable prognostic marker even in the initial assessment of a patient

  2024cites this paper
• Efficacy of a WeChat-Based, Multidisciplinary, Full-Course Nutritional Management Program on the Nutritional Status of Patients With Ovarian Cancer Undergoing Chemotherapy: Randomized Controlled Trial

  2024cites this paper
• Biomarkers in high grade serous ovarian cancer.

  2024cites this paper
• PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy.

  2024cites this paper
• Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant Chemotherapy

  2024cites this paper
• Correlation between plasma PSGL‐1 and FIGO stage, tumor metastasis, and survival in epithelial ovarian cancer

  2024cites this paper
• Exploring the Potential of Natural Killer Cell-Based Immunotherapy in Targeting High-Grade Serous Ovarian Carcinomas

  2024cites this paper
• Lactate activates CCL18 expression via H3K18 lactylation in macrophages to promote tumorigenesis of ovarian cancer

  2024cites this paper
• Targeted DNA sequencing of high‐grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression

  2024cites this paper
• Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer

  2024cites this paper
• A novel approach for the quantification of single-cell adhesion dynamics from microscopy images

  2024cites this paper
• Real‐world data of poly (ADP‐ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

  2024cites this paper
• Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer

  2024cites this paper
• Establishment of an ovarian cancer exhausted CD8+T cells-related genes model by integrated analysis of scRNA-seq and bulk RNA-seq

  2024cites this paper
• Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer

  2024cites this paper
• P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.

  2023cites this paper
• Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway

  2023cites this paper
• Mechanisms of Regulation of the Expression of miRNAs and lncRNAs by Metformin in Ovarian Cancer

  2023cites this paper
• A Rare Case of Krukenberg Tumor in a Young Female Initially Misdiagnosed as Ovarian Tuberculosis

  2023cites this paper
• Fabricating a low-temperature synthesized graphene-cellulose acetate-sodium alginate scaffold for the generation of ovarian cancer spheriod and its drug assessment

  2023cites this paper
• Liposomal delivery of gene therapy for ovarian cancer: a systematic review

  2023cites this paper
• Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer

  2023cites this paper
• Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

  2023cites this paper
• Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer

  2023cites this paper
• An Overview of Ovarian Cancer: The Role of Cancer Stem Cells in Chemoresistance and a Precision Medicine Approach Targeting the Wnt Pathway with the Antagonist sFRP4

  2023cites this paper
• Targeting ovarian cancer stem cells: a new way out

  2023cites this paper
• Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies

  2023cites this paper
• CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer

  2023cites this paper
• Ultrasound boosts doxorubicin efficacy against sensitive and resistant ovarian cancer cells.

  2023cites this paper
• Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap

  2023cites this paper
• Frontiers of Ovarian Carcinosarcoma

  2023cites this paper
• Elevated expression of EAPP is associated with poor prognosis and promotes tumor progression in epithelial ovarian cancer

  2023cites this paper
• Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines

  2023cites this paper
• Expression status and prognostic significance of mitochondrial dynamics OPA3 in human ovarian cancer

  2022cites this paper
• Construction and validation of a histone acetylation-related lncRNA prognosis signature for ovarian cancer

  2022cites this paper
• The paradigm of drug resistance in cancer: an epigenetic perspective

  2022cites this paper
• The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells

  2022cites this paper
• Enhanced Anti-Proliferative Effect of Carboplatin in Ovarian Cancer Cells Exploiting Chitosan - Poly (lactic glycolic acid) Nanoparticles.

  2022cites this paper
• Circ_0078607 inhibits the progression of ovarian cancer via regulating the miR-32-5p/SIK1 network

  2022cites this paper
• Pharmacist-led olaparib follow-up service for ambulatory ovarian cancer patients: A prospective study in a tertiary specialized cancer hospital in China

  2022cites this paper
• The anti-ovarian carcinoma activity of l-amino acid oxidase from Crotalus adamanteus venom in vivo and in vitro

  2022cites this paper
• BCL2L1 is identified as a target of naringenin in regulating ovarian cancer progression

  2022cites this paper
• Targeted Ultrafine Iron Oxide Nanoparticles for Delivery of the Topoisomerase Inhibitor SN38 and Ovarian Cancer Treatment

  2022cites this paper
• Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy

  2022cites this paper
• Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism

  2022cites this paper
• Cytotoxic Properties of C17 Polyacetylenes from the Fresh Roots of Panax ginseng on Human Epithelial Ovarian Cancer Cells

  2022cites this paper
• Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer

  2022cites this paper
• CCL2 overexpression is associated with paclitaxel resistance in ovarian cancer cells via autocrine signaling and macrophage recruitment.

  2022cites this paper
• Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway

  2022cites this paper
• The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells

  2022cites this paper
• Glaucocalyxin A Inhibits the Malignant Progression of Epithelial Ovarian Cancer by Affecting the MicroRNA-374b-5p/HMGB3/Wnt-β-Catenin Pathway Axis

  2022cites this paper
• Mechanomimetic 3D Scaffolds as a Humanized In Vitro Model for Ovarian Cancer

  2022cites this paper
• Analysis of the Correlation between Nutritional Status and Quality of Life of Patients with Gynaecological Ovarian Cancer during Postoperative Chemotherapy

  2022cites this paper
• Complex molecular profile of DNA repair genes in epithelial ovarian carcinoma patients with different sensitivity to platinum-based therapy

  2022cites this paper
• Synthesis, characterization, and biological application of some transition metal complexes of N'-(benzo[d][1,3]dioxol-5-ylmethylene)isonicotinohydrazide

  2022cites this paper
• Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma

  2022cites this paper
• Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer

  2021cites this paper
• MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway

  2021cites this paper
• Non-Coding RNAs as Biomarkers of Tumor Progression and Metastatic Spread in Epithelial Ovarian Cancer

  2021cites this paper
• FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo

  2021cites this paper
• Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting

  2021cites this paper
• Sevoflurane and Desflurane Exposure Enhanced Cell Proliferation and Migration in Ovarian Cancer Cells via miR-210 and miR-138 Downregulation

  2021cites this paper
• LncRNA HOXC-AS3 Suppresses the Formation of Mature miR-96 in Ovarian Cancer Cells to Promote Cell Proliferation

  2021cites this paper
• Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway

  2021cites this paper
• [EEFSEC knockdown inhibits proliferation, migration and invasion of prostate cancer cells in vitro].

  2021cites this paper
• The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes

  2021cites this paper
• Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

  2021cites this paper
• The anti-ovarian carcinoma activity of L-amino Acid Oxidase from Crotalus adamanteus venom in vivo and in vitro

  2021cites this paper
• Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer

  2021cites this paper
• FBXO22 Promotes Growth and Metastasis and Inhibits Autophagy in Epithelial Ovarian Cancers via the MAPK/ERK Pathway

  2021cites this paper
• In vitro Study of Radiosensitivity Effects of Galbanic Acid on Ovarian Tumor Cells (OVCAR-3 Cell Line)

  2021cites this paper
• Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers

  2021cites this paper
• Ovarian cancer health politics in Romania and Germany: A comparative study.

  2021cites this paper
• Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein

  2021cites this paper
• miR-152-mediated MKK7 downregulation is attenuated by MYCNOS in ovarian adenocarcinoma

  2021cites this paper
• LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer

  2021cites this paper
• LncRNA SRA mediates cell migration, invasion, and progression of ovarian cancer via NOTCH signaling and epithelial–mesenchymal transition

  2021cites this paper
• Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials

  2021cites this paper
• Polypeptide LTX‐315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin‐1/PI3K/mTOR signaling pathway

  2021cites this paper
• Neurotoxin Botulinum Inserts Apoptotic Effects on Certain Cancer Cell Lines Via Neural Niche of Tumors: A Molecular Study

  2020cites this paper